In recent years, the United States has witnessed a sharp increase in prices, with everyday essentials like food and gasoline experiencing continuous cost surges. The rise is expected to further extend into the health insurance sector, particularly with employer-sponsored insurance, where significant increases in premiums are anticipated for the upcoming year. Employers are likely to pass on much of the upcoming increases to their employees.
Currently, approximately 157 million people in the U.S. are covered by employer-provided health insurance. Analysts predict that premiums for employer-sponsored insurance could see an increase of up to 9.5% next year. However, experts believe that the actual rise may be lower than this forecast.
According to the most recent analysis from the Kaiser Family Foundation (KFF), the average annual premium for employer-provided family health insurance stands at $28,303, which marks a 5% rise compared to the previous year. Employees are feeling the pinch even more, with their average share of the premium increasing by 9%, coming to nearly $7,470 annually.
Matthew Rae, the Deputy Director of the KFF Health Insurance Market Project, highlighted that many Americans with employer-sponsored health insurance are now struggling to afford their premiums.
Meredith Rosenthal, a professor specializing in health economics and policy at Harvard University, pointed out that both medications and medical exam costs are significantly higher in the U.S. compared to other developed nations.
Over the past five years, inflation in the U.S. has mirrored increases in wages and health insurance premiums, but employees still shoulder nearly a quarter of the total costs of employer-sponsored family health insurance.
A KFF analysis indicated that among large companies offering health insurance, 44% have raised the proportion that employees are required to pay due to rising costs.
An article recently published by PBS identified three key reasons behind the persistent rise in healthcare costs in the United States. It pointed out that fifteen years ago, the average annual premium for employer-sponsored family health insurance was $15,220, with employees covering about $4,190.
Experts believe that the increase in health insurance premiums stems from both long-term trends and newer factors emerging in recent years. They assert that rising rates imposed by insurance companies are not the primary driver; rather, it is the exorbitant pricing of medical services that is at the heart of the issue.
Zack Cooper, an associate professor of public health and economics at Yale University, found that average price increases among U.S. insurance companies were about 19% in 2011 and have since decreased to nearly 15% by 2024. Over the past thirteen years, average health insurance premiums have cumulatively increased by 91%, with medical service prices being the primary cause.
Experts point out that the increase in healthcare costs is driven by multiple factors, including rising tariffs and energy prices. A considerable degree of price autonomy exists among healthcare providers, including hospitals and pharmaceutical companies, leading to limited regulation. In this environment, market competition is essential for curbing prices, yet the outcomes are often less than satisfactory.
For example, prices for MRI scans in the private healthcare market can be twice as high as the Medicare reimbursement rates, where negotiations are possible.
Cooper noted that another contributing factor to soaring healthcare costs is the inadequate antitrust regulation in the U.S. In recent years, there has been a trend of mergers among hospitals and clinics, resulting in a highly concentrated healthcare market. His research indicated that from 2002 to 2020, over 1,000 hospitals across the nation merged, yet the Federal Trade Commission (FTC) only pursued enforcement actions in 13 of those cases.
He stressed that hospital mergers typically benefit the institutions involved but may not serve the public well. In the absence of competition post-merger, healthcare costs frequently rise rather than fall. Fundamentally, controlling health insurance premiums requires controlling healthcare spending.
Experts contend that the recent surge in medical expenditures may be attributed to an increase in the frequency of healthcare services used. While the reasons behind this uptick are not entirely clear, it may be linked to growing public dissatisfaction with the prior authorization (PA) process, prompting insurance companies to reduce PA usage, which in turn increased the frequency of medical service utilization.
Data from the Centers for Disease Control and Prevention (CDC) indicates that the number of individuals using prescription drugs in the U.S. has increased compared to 2019.
Furthermore, the aging population in America is driving up healthcare demands. With a rise in the elderly demographic, chronic illnesses and other health conditions are becoming more prevalent, thus contributing to long-term increases in healthcare spending.
Post-COVID-19, there has been a slight rebound in healthcare services such as check-ups, health management, and hospitalizations, which may have further contributed to the substantial increase in healthcare expenses seen in recent years.
Experts also point out that another factor pushing up drug prices is the high demand for GLP-1 receptor agonist medications. These drugs, used for managing diabetes and obesity, are newly developed and still under patent protection, creating a significant market demand.
Additionally, some promising new cancer therapies and specialized medications are exceedingly expensive, leading to exorbitant drug costs. Over the past decade, these specialized medications have become a crucial element in the overall growth of healthcare expenditure. While they represent a small fraction of total spending, their rapid price increase is notable.
A Gallup poll conducted in July revealed that 15% of Americans have used GLP-1 drugs for weight loss. By 2026, this number is projected to rise to 11%, an increase from 3% in 2024.
The Gallup survey further discovered a slight decline in obesity rates in the U.S., with nearly 40% of the population classified as obese in 2022, dropping to 36.8% this year. The proportion of diagnosed diabetes remains stable at 12.8%.
However, the KFF survey highlighted that many employers do not reimburse GLP-1 weight loss medications. Among companies with over 200 employees, fewer than one in five offer insurance coverage for such medications. In larger enterprises with over 5,000 employees, the figure rises to a third.
Employers’ reluctance to reimburse these medications likely stems from their high costs. Six percent of employers stated that GLP-1 drugs severely impact their prescription drug expenditures. In companies with more than 5,000 employees, this figure climbs to 93%, with 61% deeming the impact significant. Many employers believe the prices of these drugs are exorbitant and have announced that they will not cover weight loss medications in the future.
Experts suggest that the rise in healthcare spending attributed to GLP-1 medications might just be a short-term phenomenon. A wave of patent expirations for many GLP-1 drugs is anticipated to begin in 2032, potentially leading to a decrease in drug prices. However, as new and more advanced GLP-1 medications continue to emerge, the overarching issue may not be fully resolved.
Experts assert that the ongoing introduction of new drugs and therapies remains a primary driver of long-term healthcare spending growth. Nevertheless, as new pharmaceutical companies produce next-generation drugs, competition among various brands could contribute to price reductions.
However, pharmaceutical companies can still maintain market dominance by restricting insurance reimbursement for their drug lists and utilize clinical trials to demonstrate superior efficacy for particular patient subgroups.
The ongoing release of multiple new drugs may yield some benefits, but competition among pharmaceutical companies often resembles an escalating arms race, requiring considerable investment and ultimately resulting in high drug prices.